- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07913412
High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes (PRIME)
High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes; PRIME: P: Precision R: Radiosurgery I: Intervention M: Minimal Invasive Surgical Approach E: EYESIGHT
High-precision radiosurgery followed by minimally invasive surgical approach in patients with high-prominence uveal melanomas: modern radiation techniques and outcomes. Evaluation of outcome regarding multiparametric parameters and co-factors
Study Overview
Status
Detailed Description
The aim here is to prospectively evaluate modern technical standards. The aim of this study is to assess the influence of the updated basic diagnostics and high-resolution diagnostics for radiation planning and the new technical therapy standards (therapy options in application: volume modulated rapid arc technique (VMAT) / online arc technique (VMAT) / online onboard image-guidance (IGRT), by means of the newly established Clinic for Radiation Therapy 2019-2021) depending on known prognostic parameters for quality assurance of the long-term outcome (overall survival, local tumor control). This will lay the basis for standardizing treatment parameters as far as possible, but also to introduce improvements in the treatment of future patients.
Scientific background (state of research (with literature references) and
Derivation of the research question (rationale)):
The eye can be affected by several neoplastic processes, which can lead either primarily or secondary to systemic metastasis. The most common primary tumors of the eye include conjunctival melanoma and uveal melanoma. Metastases from systemic malignant diseases, particularly of the breast and lungs, can also affect the eye.
A combination of ophthalmologic examination, MRI and additional tests and cytologic/histopathologic evaluation leads to an accurate diagnosis.
Depending on the tumor manifestation, treatment consists of a multimodal concept. In the case of uveal melanomas and the aim of preserving the globe and and visual acuity preservation, radiotherapy is one of the most important treatment modalities that can be applied.
In the last 20 years, radiotherapy has developed rapidly away from two-dimensional modulated, three-dimensional techniques. But here too the high level of technical diversity in radiotherapy and ever newer technical innovations, there is a broad spectrum of radiotherapy. Standard therapy can be performed using modern devices, the high-precision stereotactic linear accelerators (irradiation devices), can be safely further optimized. This is to be tested in the Department of Radiotherapy.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Maja Guberina, PD MD
- Phone Number: 0201 723 83121
- Email: maja.guberina@uk-essen.de
Study Locations
-
-
-
Essen, Germany
- Recruiting
- University Hospital Essen
-
Contact:
- Maja Guberina
- Phone Number: +4920127232321
- Email: maja.guberina@uk-essen.de
-
Essen, Germany, 45147
- Recruiting
- Maja Guberina
-
Contact:
- Maja W Strahlentherapie
- Phone Number: +492017232321
- Email: maja.guberina@uk-essen.de
-
-
Germany / NRW
-
Essen, Germany / NRW, Germany, 45147
- Recruiting
- Department for Radiotherapy, University Hospital Essen, National Center for Tumor Diseases (NCT) West
-
Contact:
- Maja Guberina, PD Dr. med. (MD), specialist
- Phone Number: +492017232321
- Email: maja.guberina@uk-essen.de
-
Contact:
- Ina Grübel
-
Principal Investigator:
- Maja Guberina, PD Dr. med. (MD)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Inclusion Criteria:
- Resectability, high-prominent and high risk uveal melanoma
Exclusion Criteria:
- EOE
- lux defect (If a medical report notes a "lux defect" alongside this, it refers to a deficit in light perception (from the Latin lux for light). It means the eye's ability to sense light, darkness, or light direction is impaired)
Description
Inclusion Criteria:
- Functional Resectability,
- Technical Resectability
- high-prominent uveal melanoma
Exclusion Criteria:
- EOE
- At least in part remaining eye function that can be saved
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Local control
Time Frame: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Local control |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Function: Visual acuity:
Time Frame: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Visual function assessed separately for each eye. Visual acuity: decimal scale,range 2,0 - 0,01: decimal acuity scale |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Quality of Life, ophthalmic cancer-specific quality of life
Time Frame: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Quality of Life, ophthalmic cancer-specific quality of life 1) EORTC QLQ-OPT30 (ophthalmic cancer-specific quality of life): Scores range from 0-100; higher scores indicate greater visual impairment, ocular symptoms, and functional difficulties. |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Progression Free Survival
Time Frame: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Progression Free Survival |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Overall Survival
Time Frame: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Overall Survival |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Function: Visual acuity:
Time Frame: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Visual function assessed separately for each eye. Visual acuity: decimal scale,range 2,0 - 0,01: decimal acuity scale; furthermore, 1.Count-fingers, 2.hand-motion and 3.light-perception categories are recorded separately when acuity cannot be quantified: for each item: value yes / no |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Function: Visual field
Time Frame: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Visual field: Automated perimetry, Visual Field Index (VFI, %): 0 % - 100%, |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Quality of Life general quality of life
Time Frame: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
EORTC QLQ-C30 (general quality of life): Scores range from 0-100; A) higher scores indicate better functioning/global quality of life B) symptom scores: indicate greater symptom burden on symptom scales. |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Function: Retinal Nerve Fiber Layer
Time Frame: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Optical coherence tomography (OCT): Peripapillary retinal nerve fiber layer (RNFL) thickness, measured in µm and classified in percentiles (regarding normal values) |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Cornea
Time Frame: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
corneal outcome: thickness measured in µm |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Cornea
Time Frame: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Corneal outcome modified Stocker's classification: category 0 No damage no injury category 1 corneal guttae without epithelial or stromal edema. category 2 corneal guttae with epithelial or stromal edema. category 3 corneal edema associated with scar formation. category 4 corneal opacification with neovascularization, modified Stocker's classification |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
|
Corneal overall outcome classification
Time Frame: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
category 0 No corneal-ulcus category 1 Irregular punctate epithelial defects category 2 Non-healing epithelial defects / persistent epithelial defect (PED) category 3 Ulcer perforation |
At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-10377-BO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
dependent on the project
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.